Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis

HEINER APPEL, PEIHUA WU, REBECCA SCHEER, CLAUDIA KEDOR, BIRGIT SAWITZKI, ANDREAS THIEL, ANDREAS RADBRUCH, JOACHIM SIEPER, and UTA SYRBE

ABSTRACT. Objective. Regulatory T cells are characterized by expression of the transcription factor FoxP3 and are thought to be involved in the pathogenesis of autoimmune diseases. We determined the frequency and phenotypic characteristics of CD4+FoxP3+ T cells in the blood and synovial fluid (SF) of patients with inflammatory joint diseases.

Methods. SF from 10 patients with ankylosing spondylitis (AS), 20 patients with other spondyloarthritides or with peripheral arthritis (pSpA), and 12 patients with rheumatoid arthritis (RA), and peripheral blood (PB) from 22 patients with AS, 19 with pSpA, 15 with RA, and 12 healthy controls were stained for CD4, FoxP3, CD25, and CD127 and different effector cytokines and then analyzed by flow cytometry. Methylation pattern of the Treg-specific demethylated region (TSDR) was determined after bisulfite treatment by quantitative polymerase chain reaction.

Results. In all groups of patients we observed higher frequencies of Foxp3+ cells/CD4+ T cells within SF compared to PB. The frequency of synovial Foxp3+ cells/CD4+ T cells was significantly higher in patients with pSpA (18.79% ± 6.41%) compared to patients with AS (9.69% ± 4.11%) and patients with RA (5.95% ± 2.21%). CD4+FoxP3+ T cells were CD25+ and CD127– and lacked effector cytokine production in any of the different patient groups. The majority of the CD4+CD25+CD127– T cells showed demethylation of the TSDR within the Foxp3 locus, confirming its regulatory phenotype.

Conclusion. Our data show accumulation of Foxp3+ T cells within inflamed joints. These Foxp3+ T cells are mainly of stable T regulatory phenotype. The high frequency of Foxp3+ T cells in pSpA might contribute to the spontaneous resolution and remitting course of arthritis in pSpA as compared to the more persistent joint inflammation in RA. (First Release Sept 15 2011; J Rheumatol 2011;38:2445–51; doi:10.3899/jrheum.110377)

Key Indexing Terms:

FOXP3 TREG JOINT INFLAMMATION SPONDYLOARTHRITIS

The spondyloarthritides (SpA) comprise ankylosing spondylitis (AS), reactive arthritis (ReA), arthritis/spondylitis with inflammatory bowel disease, arthritis/spondylitis with psoriasis, and undifferentiated spondyloarthritis (uSpA). A high association with HLA-B27 is common among these diseases, which also share some clinical symptoms such as inflammatory back pain, asymmetrical involvement of large peripheral joints of the lower limbs, and the possible occurrence of sacroiliitis, spondylitis, enthesitis, and uveitis1. The SpA can be divided into SpA with predominant axial and SpA with predominant peripheral involvement. Both forms overlap in about 20–30% of cases2. Axial inflammation in AS is often fluctuating with a change between appearance and disappearance of inflammation at specific sites. Also, peripheral joint inflammation in SpA is usually self-limiting, but can remit and migrate from joint to joint. This is different from rheumatoid arthritis (RA), where normally persistent inflammation in the same joint is observed3.

T regulatory cells (Treg) are essential for balancing the immune response against infection and for the establishment and maintenance of self-tolerance4. Initially, CD4+ Treg were characterized by high expression levels of CD25, a component of the high-affinity interleukin 2 (IL-2) receptor4. The identification of the forkhead box transcription factor Foxp3 as a master transcription factor of Treg provided a powerful tool for Treg analysis and identification5. The transcription factor Foxp3 is necessary for the development of Treg in the thymus, and is required for the maintenance of the suppressive
function of mature peripheral Treg. In mice, FoxP3 gene mutations and FoxP3 deletion results in lymphoproliferative autoimmune disorder due to the lack of Treg. In humans, a disease called “immune dysregulation, polyendocrinopathy, enteropathy, X-linked” (IPEX) is caused by mutations in the FoxP3 gene and is associated with multiple inflammatory autoimmune organ involvement. This suggests that immune and autoimmune responses are regulated by a sensitive balance between regulatory and effector T cells.

To determine the potential effect of Treg in joint inflammation associated with SpA and RA, we analyzed the frequency and functional characteristics of FoxP3+ cells/CD4+ T cells in the peripheral blood (PB) and in the synovial fluid (SF) of patients with different forms of SpA and patients with RA.

**MATERIALS AND METHODS**

**Patients.** We obtained PB from 22 patients with AS, 19 patients with peripheral spondyloarthritis (pSpA; 8 patients with uSpA, 6 with reactive arthritis, 3 with psoriatic arthritis, and 2 with Crohn’s disease and arthritis), 15 patients with RA, and 12 healthy controls. We also analyzed SF mononuclear cells from 10 patients with AS, 20 with pSpA (8 patients with uSpA, 7 with reactive arthritis, 3 with psoriatic arthritis, and 2 with Crohn’s disease and arthritis), and 12 patients with RA. All patients with AS fulfilled the modified New York criteria, and all patients with pSpA fulfilled the European Spondylarthritids Study Group criteria. Patients’ characteristics are given in Table 1. More patients with RA than with AS or pSpA were on disease-modifying antirheumatic drug (DMARD) therapy. Matched samples of PB and SF could be analyzed from 8 patients with AS, 6 with RA, and 11 with pSpA.

All patients gave consent to the study, which was approved by the local ethics committee of the Charité Universitätsmedizin Berlin, Campus Benjamin Franklin.

**Staining for T cell surface markers, FoxP3, intracellular cytokines, and analysis by flow cytometry.** For staining of whole PB and SF, erythrocytes were lysed by incubation with Becton Dickinson Fluorescence Activated Cell Sorting (FACS) lysing solution (Becton Dickinson, Heidelberg, Germany). Then cells were washed with phosphate buffered saline/bovine serum albumin and stained for surface markers, i.e., CD4, CD25, or CD127. Foxp3 and cytokines were stained intracellularly after permeabilization using FACS™ Permeabilizing Solution (Becton Dickinson) as described. To avoid nonspecific binding, staining was performed in the presence of Beriglobin (1 mg/ml; Centeon Pharma, Berlin, Germany). The following antibodies were used: anti-human CD4 (clone SK3; Becton Dickinson), anti-FoxP3 (clone eBio64DEC17; eBioscience, San Diego, CA, USA).

**Table 1. Characteristics of patients giving samples of peripheral blood or synovial fluid.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ankylosing Spondylitis, n = 22</th>
<th>Peripheral, Non-AS Spondyloarthritis, n = 19</th>
<th>Rheumatoid Arthritis, n = 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs, mean ± SD</td>
<td>40.9 ± 13.8</td>
<td>35.2 ± 12.3</td>
<td>51.6 ± 16.2</td>
</tr>
<tr>
<td>HLA-B27+, %</td>
<td>81.8</td>
<td>52.6</td>
<td>—</td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>—</td>
<td>—</td>
<td>13/15+</td>
</tr>
<tr>
<td>ACPA+</td>
<td>—</td>
<td>—</td>
<td>9/15</td>
</tr>
<tr>
<td>Disease duration, mo, mean ± SD</td>
<td>11.3 ± 9.1</td>
<td>4.1 ± 3.8</td>
<td>6.4 ± 8.5</td>
</tr>
<tr>
<td>Medication</td>
<td>1 MTX</td>
<td>2 MTX (Crohn’s disease)</td>
<td>7 DMARD, 3 TNF-α blocker</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>32.7 ± 21.7</td>
<td>30.7 ± 23.4</td>
<td>54.1 ± 27.3</td>
</tr>
<tr>
<td>CRP, mg/ml</td>
<td>2.0 ± 3.9</td>
<td>2.5 ± 2.2</td>
<td>3.6 ± 2.7</td>
</tr>
<tr>
<td>BASDAI</td>
<td>3.44 ± 2.16</td>
<td>NA</td>
<td>5.3 ± 1.7</td>
</tr>
<tr>
<td>DAS28</td>
<td>NA</td>
<td>NA</td>
<td>5.3 ± 1.7</td>
</tr>
</tbody>
</table>

ACPA: anticitrullinated protein antibodies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; DAS28: 28-joint Disease Activity Score; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; TNF: tumor necrosis factor; DMARD: disease modifying antirheumatic drug; MTX: methotrexate.
Increased frequency of synovial FoxP3+ cells/CD4+ T cells in SpA vs RA. The percentage of Foxp3+ cells among CD4+ T cells was determined in the PB and SF of patients with RA, AS, and pSpA. There was a clear difference among the diseases in the frequency of synovial FoxP3+ cells/CD4+ T cells. The highest frequency of Foxp3+ cells/CD4+ T cells was found in patients with pSpA (9.69% ± 6.41%; p = 0.2857, p = 0.4927; RA: Spearman r = 0.3176; p = 0.2308), whereas in patients with RA (5.95% ± 2.21%; p = 0.002), the frequency of synovial Foxp3+ T cells was significantly higher than in AS (5.95% ± 2.21%; p = 0.002; Figure 1A). Among patients with pSpA, no difference in the frequency of Foxp3+ cells/CD4+ T cells was found between patients with axial involvement and patients without axial involvement (data not shown). Comparing AS and RA, significantly higher frequencies of synovial Foxp3+ cells/CD4+ T cells were observed in patients with AS (p = 0.007).

In contrast to synovial Foxp3+ T cells, no significant differences were found in the frequency of PB Foxp3+ cells/CD4+ T cells in patients with RA, AS, and pSpA (all p > 0.05). Moreover, none of the different groups of patients showed a significant difference of blood FoxP3+ cells/CD4+ T cells compared to healthy controls (all p > 0.05; Figure 1B).

Increased frequencies of FoxP3+ cells/CD4+ T cells in synovial fluid compared to peripheral blood. The previous data suggested that Foxp3+ T cells are enriched within the SF compared to blood. To study this in more detail we analyzed matched PB and SF samples from 6 patients with RA, 8 with AS, and 11 with pSpA. As shown in Figure 2, the frequency of Foxp3+ T cells/CD4+ T cells was higher in SF compared to PB in most of the patients, no matter whether they had RA, AS, or pSpA. In line with the previous data, we observed the most prominent accumulation of Foxp3+ T cells/CD4+ T cells in the SF of patients with pSpA.

By analyzing data of all patients with simultaneous measurement of C-reactive protein (CRP) as a marker for disease activity, a correlation of the percentage of PB Foxp3+ cells/CD4+ T cells and CRP was found in patients with pSpA (Spearman r = 0.7608; p = 0.0065), but not in patients with AS (Spearman r = 0.3176; p = 0.2308), nor in patients with RA (Spearman r = 0.2308; p = 0.4273). Synovial fluid Foxp3+ cells/CD4+ T cells did not correlate to CRP in all groups of patients, although there was a trend in patients with pSpA (pSpA: Spearman r = 0.4750, p = 0.0736; AS: Spearman r = 0.2857, p = 0.4927; RA: Spearman r = 0.1538, p = 0.6331).

CD4+FoxP3+ T cells do not secrete effector cytokines. In addition to its presence on regulatory T cells, Foxp3 is temporarily expressed on activated T cells. To demonstrate that the T cells detected by Foxp3 staining within the blood and in particular in the inflamed tissue are indeed regulatory T cells, we analyzed whether synovial CD4+Foxp3+ T cells secrete effector cytokines spontaneously or after stimulation with SEB.

As shown in Figure 3, CD4+Foxp3+ T cells did not secrete effector cytokines such as IL-2, IFN-γ, tumor necrosis factor-α (TNF-α), or IL-10 either spontaneously or after SEB stimulation in any of the different patient groups (Figure 3). In contrast, cytokine production was readily detectable among CD4+Foxp3− T cells.
we determined the percentage of TSRD demethylation in CD4+CD25+ MACS-enriched or CD4+CD25+CD127– FACS-sorted T cells in the blood of 2 patients with AS and in SF of 4 patients with AS and adjusted the content of non-methylated TSDR to the percentage of CD4+CD25+CD127– T cells as putative Treg in the sample. As shown in Figure 4C, more than 80% of the CD4+CD25+CD127– T cells of SF samples and more than 90% of the CD4+CD25+CD127– T cells in the blood of patients with AS showed demethylation within the TSDR, indicating that the majority of CD4+CD25+CD127– T cells, from both blood and inflamed tissue of patients with SpA, indeed represent Treg.

**DISCUSSION**

There is increasing evidence that Treg compartmentalization and trafficking may be specific for distinct sites of inflammation, resulting in a specific retention of Treg at inflamed sites that require immune regulation. Therefore, we determined the distribution of Foxp3+ T cells in PB and in the inflamed joints of patients with pSpA, AS, or RA. In PB we did not observe enhanced Treg numbers in any of the diseases compared to healthy controls. In contrast, we found higher frequencies of Foxp3+ cells/CD4+ T cells in the inflamed joint fluid compared to PB in patients with RA, AS, and pSpA, suggesting that regulatory T cells accumulate within the inflamed joints.
Contradictory results about the frequency of peripheral and SF Treg are reported in different inflammatory joint diseases, but especially in RA. In RA the frequency of CD4+CD25high+ Treg was reported to be higher in the SF than in the PB using matched samples15,16, similar to our findings, while others reported no difference in the frequency of Treg in both compartments17 in unmatched patients with RA. Statistical analysis of our unmatched samples from patients with RA also did not show significant differences (data not shown), suggesting that the comparison of matched samples is superior in identifying small differences.

As Foxp3 is also transiently expressed on activated T cells, we gained further evidence for the “true” Treg origin of the cells identified by Foxp3 staining in patients with inflammatory joint disease by further characterizing these cells. We showed that these cells coexpressed the high-affinity IL-2 receptor CD25 but lacked expression of CD127, the IL-7 receptor that is considered a specific feature of Treg11,12. Further, it is well documented that Treg cells fail to proliferate or produce effector cytokines such as IFN-γ or TNF-α, nor do they produce IL-2 in response to T cell receptor stimulation18. We proved that the CD4+Foxp3+ T cells, neither those from blood nor from SF, produce cytokines such as IL-2, IFN-γ, or TNF-α. Also at the genomic level, i.e., by analyzing TSDR demethylation and phenotypic characteristics, as well as the lack of cytokine secretion of Foxp3+ T cells within the joints, our data suggest that most of the Foxp3+ T cells are Treg. The numeric differences in synovial Foxp3+ T cells among various forms of joint inflammation point to differences in the immunological mechanisms regulating joint inflammation.

**REFERENCES**


Figure 3. Synovial fluid CD4+FoxP3+ T cells do not secrete tumor necrosis factor-α, interferon-γ, interleukin 2 (IL-2), or IL-10. Synovial fluid cells were stimulated in the absence or presence of staphylococcus enterotoxin B (SEB), and cytokine production and Foxp3 expression among gated CD4+ T cells was determined by intracellular staining. An example of cytokine secretion in relation to Foxp3 expression of CD4+ T cells without (A) and with (B) stimulation is shown. Numbers indicate the frequency of cells/quadrant. A summary of all analysis in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and peripheral spondyloarthritis (pSpA) is shown in C.


Figure 4. The majority of CD4+Foxp3+ T cells exhibits characteristics of regulatory T cells. The frequency of CD25+ cells among CD4+Foxp3+ T cells was determined in peripheral blood T cells of patients with rheumatoid arthritis, ankylosing spondylitis (AS), and peripheral spondyloarthritis (pSpA; A). The control staining is shown in the upper panel; the positive staining is shown in the lower panel. Numbers indicate the percentage of cells/quadrant on gated CD4+ T cells. Synovial T cells of 2 patients with AS and 1 patient with pSpA were stained for CD127 in relation to Foxp3 expression (B). Numbers indicate the percentage of cells/quadrant in gated CD4+ T cells. C. Demethylation of the Treg-specific demethylated region (TSDR) within the Foxp3 locus was determined for CD4+CD25+CD127+ T cells isolated from peripheral blood (PB; n = 2) or synovial fluid (SF; n = 4) of patients with AS.